The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2021 | A look into the future: CAR-T and bispecifics in myeloma
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, discusses the future of CAR T-cell therapy and bispecific monoclonal antibodies in multiple myeloma. When approved, the optimal use for these therapies would be in triple-refractory myeloma patients, but these strategies will move into earlier lines of treatment in the future. Currently, ongoing clinical trials are evaluating the role of bispecifics and CAR T-cells following one/three prior lines of therapy. While other trials are evaluating the safety and efficacy of CAR T-cells in the front-line setting in patients with high-risk myeloma. Dr Mateos highlights different strategies, currently being investigated in preliminary clinical trials, to improve the efficacy of BCMA CAR T-cells. In the bispecific antibody field, new targets beyond BCMA are being investigated, including GPRC5D-directed bispecifics, as well as novel combinations of immune and targeted therapies. This interview took place during the 3rd European CAR T-cell Meeting.
